HDAC9 and glioblastoma: While the current preclinical evidence regarding HDAC inhibition in GBM is encouraging, clinical trials with the current generation of HDAC inhibitors have shown a mixture of outcomes with modest benefit in some trials and disappointing results in others due to unanticipated toxicity or failure to fill study arms (85).